PriceTargets.com logo

Evofem Biosciences - evfm Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.01 As of 09/27/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for EVFM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evofem Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVFM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVFM

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Evofem Biosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.01.

This chart shows the closing price for EVFM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Evofem Biosciences. This rating has held steady since August 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/6/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/13/2023LaidlawReiterated RatingBuy ➝ Hold
10/12/2022Stifel NicolausDowngradeBuy ➝ Hold
8/15/2022HC WainwrightBoost TargetBuy$500.00
6/2/2022LaidlawInitiated CoverageBuy$437.50
4/12/2022Morgan StanleyBoost TargetUnderweight$993.75 ➝ $1,068.75
3/4/2022Morgan StanleyBoost TargetUnderweight$937.50 ➝ $993.75
1/31/2022HC WainwrightReiterated RatingBuy$3,750.00
1/13/2022HC WainwrightReiterated RatingBuy$3,750.00
11/16/2021HC WainwrightLower TargetBuy$4,687.50 ➝ $3,750.00
10/21/2021HC WainwrightReiterated RatingBuy$7,500.00 ➝ $4,687.50
10/14/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight
8/12/2021Morgan StanleyLower TargetEqual Weight$5,625.00 ➝ $1,875.00
6/7/2021HC WainwrightLower TargetBuy$13,125.00 ➝ $7,500.00
3/8/2021HC WainwrightLower TargetBuy$15,000.00 ➝ $13,125.00
10/1/2020Stifel NicolausInitiated CoverageBuy$9,375.00
8/20/2020Morgan StanleyInitiated CoverageEqual Weight$5,625.00
8/10/2020OppenheimerBoost TargetOutperform$33,750.00 ➝ $46,875.00
6/9/2020HC WainwrightLower TargetBuy$20,625.00 ➝ $16,875.00
6/8/2020Piper SandlerInitiated CoverageOverweight$20,625.00
5/31/2020Royal Bank of CanadaReiterated RatingBuy
5/27/2020OppenheimerBoost TargetOutperform$43,125.00 ➝ $46,875.00
5/27/2020HC WainwrightReiterated RatingBuy$20,625.00
5/25/2020OppenheimerInitiated CoverageBuy$43,125.00
5/22/2020Cantor FitzgeraldReiterated RatingBuy$16,875.00
5/7/2020OppenheimerReiterated RatingBuy
3/25/2020Royal Bank of CanadaReiterated RatingBuy$11,250.00
12/18/2019HC WainwrightReiterated RatingBuy$20,625.00
12/11/2019HC WainwrightReiterated RatingBuy$16,875.00 ➝ $20,625.00
11/27/2019HC WainwrightReiterated RatingBuy$16,875.00
10/17/2019HC WainwrightReiterated RatingBuy$16,875.00
10/16/2019Cantor FitzgeraldReiterated RatingOverweight$16,875.00
(Data available from 9/28/2019 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/30/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Evofem Biosciences logo
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.01
Low: $0.01
High: $0.01

50 Day Range

MA: $0.01
Low: $0.01
High: $0.01

52 Week Range

Now: $0.01
Low: $0.01
High: $0.23

Volume

1,380,452 shs

Average Volume

987,360 shs

Market Capitalization

$828.29 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Evofem Biosciences?

The following equities research analysts have issued reports on Evofem Biosciences in the last twelve months: Laidlaw.
View the latest analyst ratings for EVFM.

What is the current price target for Evofem Biosciences?

0 Wall Street analysts have set twelve-month price targets for Evofem Biosciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Evofem Biosciences in the next year.
View the latest price targets for EVFM.

What is the current consensus analyst rating for Evofem Biosciences?

Evofem Biosciences currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EVFM, but not buy more shares or sell existing shares.
View the latest ratings for EVFM.

What other companies compete with Evofem Biosciences?

Other companies that are similar to Evofem Biosciences include Neptune Wellness Solutions, Aravive, GT Biopharma, Sonnet BioTherapeutics and TransCode Therapeutics. Learn More about companies similar to Evofem Biosciences.

How do I contact Evofem Biosciences' investor relations team?

Evofem Biosciences' physical mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company's listed phone number is (858) 550-1900 and its investor relations email address is [email protected]. The official website for Evofem Biosciences is www.evofem.com. Learn More about contacing Evofem Biosciences investor relations.